(Reuters) -Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, its drug for hallucinations and delusions associated with Parkinson’s disease.

The decision supports a December 2023 ruling from the U.S. District Court of Delaware, ensuring the patent remains protected in Acadia’s legal battle against India-based drugmaker MSN Laboratories.

The appeals court followed a precedent that says an earlier patent claim cannot be invalidated by a later one if they share the same priority date.

“We are gratified that the U.S. Federal Appeals Court has affirmed the lower court’s ruling in favor of our composition of matter patent for Nuplazid, securing protection into 2030 for this patent, and beyond based on the recent favorabl

See Full Page